Continuous ADT Use for Prostate Cancer Quantified
Researchers estimate that nearly 189,000 men with nonmetastatic prostate cancer (PCa) in the U.S. are actively receiving continuous androgen deprivation therapy (ADT) for six months or more, according to an online report in Urology.
Karynsa Cetin, MPH, and colleagues at Amgen Inc., in Thousand Oaks, Calif., reviewed data on men aged 18-64 years enrolled in commercial health plans and men aged 67 and older enrolled in fee-for-service (FFS) Medicare. They found that 11,935 commercially insured men aged 45-64 and 115,468 FFS Medicare patients aged 65 and older were actively receiving continuous ADT for six months or more for nonmetastatic PCa. Extrapolating to the U.S. male population aged 45 and older, the investigators' estimate grew to 188,916.
The researchers noted that their investigation is the first comprehensive assessment of the number of men exposed to continuous ADT in the nonmetastatic setting in the U.S.